Gilead scraps a PhII/III study ear­ly as drug flops against ul­cer­a­tive col­i­tis

Just as Gilead $GILD was look­ing to buoy ex­pec­ta­tions in its R&D prospects, the big biotech had been hit with a set­back on its late-stage pipeline. The com­pa­ny says it’s scrap­ping a Phase II/III ul­cer­a­tive col­i­tis study of its an­ti-MMP9 an­ti­body GS-5745 af­ter track­ing in­suf­fi­cient ef­fi­ca­cy to keep it in the clin­ic.

The Da­ta Mon­i­tor­ing Com­mit­tee made the call af­ter re­view­ing the ex­pe­ri­ences of 150 pa­tients in the study, which was sup­posed to re­cruit 1,600 pa­tients al­to­geth­er. Gilead signed off on the de­ci­sion af­ter agree­ing with their con­clu­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.